

Technology Advisory Interests Register

Topic: Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma [ID6202]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Mike Chambers	TAC Committee Member	Indirect - Financial	I have attended an advisory board for Accord (comparator mfr) in an unrelated disease area (small-cell lung cancer) and an advisory panel for Pfizer (comparator mfr) in an unrelated disease area (prostate cancer).	11/06/2025 23/09/2025	It was agreed that Mike's declaration would not prevent them from participating in discussions on this appraisal.
Stella O'Brien	TAC Committee Member	Indirect - Non-financial professional	I'm a member of the Genetics Alliance UK PPIE Working Group on ATMPs affiliated with CATAPULT cell and gene therapy to encourage the integration of PPIE throughout the research cycle from the earliest stages and onwards. CATAPULT is a network of not-for profit, independent centres which connect businesses with the UK's research and academic communities. Although CAR-T therapies are an example of ATMPs, I have not contributed to work on CAR-T therapies with this group. However, the working group provided a letter	11/06/2025 24/09/2025	It was agreed that Stella's declaration would not prevent them from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			of support to a (now funded) MRC research project led by The Christie and Poolbeg Pharma that is evaluating the impact of a drug to treat the side-effects of the bispecific, elranatamab. These side-effects are cytokine release syndrome and immune effector cell neurotoxicity syndrome.		
Pedro Saramago Goncalves	TAC Committee Member	Indirect - Financial	<p>I would like to declare that I have done some health economics work in an advisory capacity for accord healthcare (with potential comparators on both topics) in an unrelated disease area (lung cancer).</p> <p>I would like to declare that in the last 12 months I have worked with Vantive (a company previously owned by Baxter, which has a potential comparator for this technology appraisal) but in an unrelated indication - medical device for mechanical ventilation.</p>	12/062025 24/09/2025	It was agreed that Pedro's declaration would not prevent them from participating in discussions on this appraisal.
Elizabeth Thurgar	TAC Committee Member	Indirect - Financial	<p>In the last 12 months I have worked with BMS (a listed comparator company) in an unrelated indication, myelodysplastic syndrome</p> <p>- In the last 12 months I have worked</p>	12/062025 23/09/2025	It was agreed that Elizabeth's declaration would not prevent them from participating in

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			with Gilead (a listed comparator company) in an unrelated indication, MASH - In the last 12 months I have worked with Pfizer, a listed comparator company, in an unrelated indication, non-small cell lung cancer.		discussions on this appraisal.
Kate Ren	TAC Committee Member	Indirect - Financial	I provided statistical methodology consultancy service to a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis). Our team has received research funding from a possible comparator company Eli Lilly to support stats methodological development in HTA. This funding is unrelated to any specific treatment or disease area.	15/06/2025 23/09/2025	It was agreed that Kate's declaration would not prevent them from participating in discussions on this appraisal.
Satish Venkateshan	TAC Committee Member	Direct - financial	Regeneron is developing REGN5837 CD22xCD28 and Odronextamab CD20xCD3 bispecific antibodies for certain B cell lymphomas including non-Hodgkin lymphoma. It is going through regulatory approval process in some of the countries already. Odronextamab has been approved	17/06/2025 23/09/2025	It was agreed that Satish's declaration would prevent them from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			by EMA for certain relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL). I work for Regeneron, pharmaceuticals/biotech company. I also own shares in the company and have stock options.		
Dr Prithwiraj Das	TAC Committee Member	Non-financial professional	I work in life sciences, including pharmaceutical market access, as Founding Director of G2PR Ltd. I have not worked on these products/indications in the last 12+ months	29/09/2025	It was agreed that Prithwiraj's declaration would prevent them from participating in discussions on this appraisal.
Cathy Burton	Expert		<ul style="list-style-type: none"> I am a Trustee for Lymphoma Action and the British Society for Haematology. I am a Co-clinical lead of national NHL audit. I am a member of the Roche steering committee. I have participated in advisory boards and provided presentations for Roche, AbbVie, Takeda and Kite. I have also participated in a speaker tour for AbbVie this year. 	14/03/2025 14/10/2025	It was agreed that Cathy's declaration would not prevent them from providing expert advice to the committee.
Sridhar Chaganti	Expert	Financial	<ul style="list-style-type: none"> I have received honoraria for advisory boards and consultancy services from 	14/03/2025 14/10/2025	It was agreed that Sridhar's declaration would not prevent them from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Roche, AbbVie, BMS-Celgene and Kite-Gilead.</p> <ul style="list-style-type: none"> • I have received speaker fees from Roche, AbbVie and Kite-Gilead. • I have received meeting attendance support from AbbVie and Kite-Gilead. 		providing expert advice to the committee.